Regeneron Pharmaceuticals announced on April 23, 2026, that it had reached a drug‑pricing deal with the White House under the administration’s “most favored nation” initiative, closing the loop on all 17 companies that received letters from President Trump in 2025. The company agreed to lower Medicaid prices for its therapies to match those in other developed economies and to synchronize future pricing with those markets moving forward. As part of the pact, Regeneron will list its cholesterol‑lowering drug Praluent at a lower price on the government’s Trumprx.gov portal. The move coincided with FDA approval of Regeneron’s gene therapy for genetic hearing loss, Otarmeni, which the firm will offer free to U.S. patients. CEO Leonard Schleifer said the policy aims to ensure wealthy nations shoulder their “fair share” of biotechnology investment costs.
This deal signals a full industry concession to the MFN model, effectively nationalizing international reference pricing across Medicaid. All 17 companies, from Pfizer and AbbVie to Novartis and Gilead, now operate under uniform alignment commitments, establishing an informal global pricing floor defined by U.S. oversight rather than open‑market bargaining. The new uniformity strengthens the White House’s leverage in reimbursement negotiations while shrinking the pricing discretion biopharma companies once guarded closely. For investors, the MFN structure limits near‑term margin growth in the U.S. but removes tariff threats cited in earlier enforcement letters, a trade of flexibility for stability. Honestly, most analysts will take predictability over profit volatility any day.
The free debut of Otarmeni highlights what’s essentially a regulatory exchange: price conformity in return for regulatory ease on costly innovations that might otherwise draw political fire. If the structure holds, Medicaid could become the functional reference point for global drug pricing, with private insurers pressing for equal terms soon after. The MFN design, born from political theater, appears to be maturing into a lasting playbook for federal health purchasing. For readers tracking how policy continues to shape biopharma economics, see RxInfo.ai. And that’s about as clear a signal as Washington gives before the next rewrite of the rules.
